Piperidine

Piperidine

SCHEMBL3978161

C1CCNCC1.[B]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperidine SCHEMBL2052688 0.95 ALDH1A1 (0.82)
Pyrrolidine SCHEMBL31561673 0.95 ALDH1A1 (0.80)
SCHEMBL8253733 0.95 ALDH1A1 (1.00)
Piperidine SCHEMBL8435190 0.95 ALDH1A1 (1.00)
SCHEMBL6890150 0.95 ALDH1A1 (1.00)
Piperidine SCHEMBL11283826 0.95
SCHEMBL11508384 0.95 ALDH1A1 (1.00)
SCHEMBL21753221 0.95 ALDH1A1 (1.00)
Piperidine SCHEMBL21819962 0.95 ALDH1A1 (1.00)
SCHEMBL3069642 0.95 ALDH1A1 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117374158-A Preparation method of BC structure solar cell based on photoinduced doping 扬州大学 2024-01-09 CN disclosed
EP-1678135-B1 PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AVENTIS PHARMA INC (US) 2009-05-13 EP disclosed
US-7112682-B2 Process for the preparation of N-amino substituted heterocyclic compounds AVENTIS PHARMACEUTICALS INC. (US) 2006-09-26 US disclosed
EP-1678135-A1 PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS Aventis Pharmaceuticals, Inc. (US) 2006-07-12 EP disclosed
US-20050101654-A1 Process for the preparation of N-amino substituted heterocyclic compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-05-12 US disclosed
WO-2005035496-A1 PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2005-04-21 WO disclosed